Work

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

Year: 2015

Type: article

Source: Lung Cancer

DOI: 10.1016/j.lungcan.2015.10.028

Authors: Susan E. Jorge, Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu S. Kobayashi, Mark S. Huberman, Daniel B. Costa

Institutions: Beth Israel Deaconess Medical Center, Harvard University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G2081079141, Overcoming resistance to tyrosine kinase inhibitors in lung cancer, Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer, SPORE in Lung Cancer, Emergence of drug resistant mutations in lung cancer, G7436035515

OpenAlex ID: W1850419181

FWCI: 11.09

Cites: 25

Cited by: 80

Related to: 10